Royalty Pharma 

Yahoo Finance • 3 months ago

3 High-Yield Dividend Stocks Down by More Than 39% to Buy Now and Hold at Least a Decade

With the major stock market indices up near all-time highs, finding stocks that pay satisfying dividend yields isn't nearly as easy as it used to be. Before you give up, though, consider Brookfield Renewable Partners(NYSE: BEP), Royalty Ph... Full story

Yahoo Finance • 4 months ago

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Royalty Pharma plc Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept.... Full story

Yahoo Finance • 4 months ago

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Ascendis Pharma Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general corporate purposes COPENHAGEN, Denmark and NEW YORK, Sept. 0... Full story

Yahoo Finance • 4 months ago

Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now?

We recently compiled a list of the 10 Best Defensive Stocks To Buy Now.In this article, we are going to take a look at where Royalty Pharma plc (NASDAQ:RPRX) stands against the other defensive stocks. Defensive stocks tend to remain stabl... Full story

Yahoo Finance • 10 months ago

Analysts Have Made A Financial Statement On Royalty Pharma plc's (NASDAQ:RPRX) Yearly Report

It's been a good week for Royalty Pharma plc (NASDAQ:RPRX) shareholders, because the company has just released its latest annual results, and the shares gained 2.3% to US$29.92. It was a weak result overall, with Royalty Pharma reporting U... Full story

Yahoo Finance • 10 months ago

Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months

Some stocks seem to hog the limelight, and that's understandable, to some extent. After all, stocks that have been at the forefront of the hottest trends and delivered tremendous gains arguably deserve greater attention than others. Howev... Full story

Yahoo Finance • 10 months ago

Royalty Pharma PLC (RPRX) Earnings Report: A Detailed Analysis

Portfolio Receipts: Q4 saw a decrease to $736 million, but FY 2023 increased by 9% to $3,049 million. Operating Activities: Net cash provided by operating activities reached $773 million in Q4 and $2,988 million for FY 2023. Transactions:... Full story

Yahoo Finance • 11 months ago

Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024

Royalty Pharma plc NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. fi... Full story

Yahoo Finance • 12 months ago

13 Most Promising Future Stocks To Buy According To Hedge Funds

In this piece, we will take a look at the 13 most promising stocks to buy according to hedge funds. If you want to skip our overview of the latest stock market news, then you can take a look at the 5 Most Promising Future Stocks To Buy. I... Full story

Yahoo Finance • last year

11 Most Promising Biotech Stocks to Buy According to Analysts

In this article, we will take a look at the 11 most promising biotech stocks to buy according to analysts. To skip our analysis of the recent trends, and market activity, you can go directly to see the 5 Most Promising Biotech Stocks to Bu... Full story

Yahoo Finance • last year

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. E... Full story

Yahoo Finance • last year

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophreniaPhase 3 data expected in the second half of 2024 NEW Y... Full story

Yahoo Finance • last year

Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophrenia Phase 3 data expected in the second half of 2024 TEL... Full story

Yahoo Finance • last year

Royalty Pharma Reports Third Quarter 2023 Results

Net cash provided by operating activities (GAAP) of $574 million and Adjusted Cash Receipts(1) (non-GAAP)of $637 million Announced transactions of up to $3.8 billion year-to-date, including $2.1 billion in upfront paymentsRaising 2023 guid... Full story

Yahoo Finance • last year

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi

Royalty Pharma purchases a portion of royalties on Roche’s Evrysdi for $1.0 billion upfrontPTC Therapeutics has option to sell rest of royalty for up to $500 million; Royalty Pharma has option to buy half of rest of royalty for up to $250... Full story

Yahoo Finance • last year

Royalty Pharma Declares Fourth Quarter 2023 Dividend

NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid... Full story

Yahoo Finance • last year

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company... Full story

Yahoo Finance • last year

10 Blue-Chip Stocks at All-Time Lows

In this article, we will take a look at the 10 blue-chip stocks at all-time lows. To see more such companies, go directly to 5 Blue-Chip Stocks at All-Time Lows. The inflation storm and subsequent rate hikes by the Federal Reserve have le... Full story

Yahoo Finance • last year

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 18th Annual BioPharma Conferenc... Full story

Yahoo Finance • last year

Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg)

Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin® (nadofaragene firadenovec-vncg) Transaction provid... Full story